Search results
Results from the WOW.Com Content Network
Prosecutors in Philadelphia issued a subpoena demanding everything related to the sale of Risperdal—business plans, emails, sales reports, clinical studies. The prosecutors had still not officially entered the qui tam cases, despite the theoretical 60-day deadline for making a decision once a relator and his lawyer filed a case in secret ...
“All the big pharmas” have lawsuits, the analyst concluded, sipping an espresso. “It’s just not a big deal.” Indeed, with before-tax profits of $20.6 billion for 2014, putting aside $500 million or even $1 billion a year over 15 years to cover payouts for boys with 46DD breasts and other claims that might come along doesn’t put much ...
As for the bottom line, Risperdal sales from 1994 through 2008 (when it went off-patent) have totaled approximately $30 billion, including approximately $20 billion in the U.S. Expenses in the U.S., including all manufacturing and sales and promotion costs, probably amounted to $2 billion based on the business plans and budgets I have seen.
Franklin and his attorney, Thomas M. Greene, filed a lawsuit, Franklin v. Parke-Davis , under the False Claims Act in federal district court in Boston. In the first off-label promotion case ever litigated in a whistleblower suit under the False Claims Act, the settlement was announced after eight years of litigation in May 2004.
Risperdal, Invega, Nesiritide: False Claims Act, FDCA 2012 Abbott Laboratories [8] $1.5 billion Off-label promotion Depakote: False Claims Act, FDCA 2009 Eli Lilly [9] $1.4 billion Off-label promotion Zyprexa: False Claims Act, FDCA 2001 TAP Pharmaceutical Products [10] $875 million Medicare fraud, kickbacks Lupron
Risperdal/Invega/ Nesiritide: Johnson & Johnson [6] $2,200,000,000 $1.72 billion civil ($2.2 billion with criminal component) Off-label promotion/kickbacks: False Claims Act/FDCA 2009 2 3 Bextra/Geodon/ Zyvox/Lyrica: Pfizer [7] $2,300,000,000 $1 billion civil ($2.3 billion with criminal component) Off-label promotion/kickbacks: False Claims Act ...
Another goal for the coming year was to “maximize and grow Risperdal’s market leadership in geriatrics and long term care.” Risperdal was already well ahead of Zyprexa in dementia market share, with 50 percent of the entire market. The goal was to boost that share still higher, to 57 percent, with sales of $302 million.
For premium support please call: 800-290-4726 more ways to reach us